Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;12(3):223-37.
doi: 10.7497/j.issn.2095-3941.2015.0020.

Development of targeted therapies in treatment of glioblastoma

Yuan-Yuan Xu  1 , Pei Gao  1 , Ying Sun  1 , You-Rong Duan  1
Affiliations
Review

Development of targeted therapies in treatment of glioblastoma

Yuan-Yuan Xu et al. Cancer Biol Med. 2015 Sep.

Abstract

Glioblastoma (GBM) is a type of tumor that is highly lethal despite maximal therapy. Standard therapeutic approaches provide modest improvement in progression-free and overall survival, necessitating the investigation of novel therapies. Oncologic therapy has recently experienced a rapid evolution toward "targeted therapy", with drugs directed against specific targets which play essential roles in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Inhibitors of these molecules have already entered or are undergoing clinical trials. However, significant challenges in their development remain because several preclinical and clinical studies present conflicting results. In this article, we will provide an up-to-date review of the current targeted therapies in GBM.

Keywords: Glioblastoma (GBM); blood-brain barrier (BBB); clinical trial; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1
Blood-brain barrier.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16:iv1-iv63. - PMC - PubMed
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. - PMC - PubMed
    1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489. - PubMed
    1. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 2009;11:403-413. - PMC - PubMed
    1. Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc 2010;48:145-152. - PMC - PubMed

LinkOut - more resources